From February 17, 2024 to March 31, 2024, the company has repurchased 3,469,900 shares, representing 0.74% for CLP 57.33 million. With this, the company has completed the repurchase of 3,469,900 shares, representing 0.74% for CLP 57.33 million under the buyback announced on February 19, 2024.
Vcanbio Cell & Gene Engineering Corp., Ltd
Equities
600645
CNE000000545
Medical Equipment, Supplies & Distribution
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
16.72 CNY | +0.24% | -4.07% | -17.51% |
1st Jan change | Capi. | |
---|---|---|
-17.51% | 1.07B | |
-8.60% | 11.98B | |
-5.68% | 8B | |
+7.10% | 5.85B | |
+27.06% | 5.54B | |
-15.84% | 3.84B | |
+10.70% | 2.66B | |
-61.53% | 2.62B | |
-8.22% | 2.33B | |
+11.29% | 2B |
- Stock Market
- Equities
- 600645 Stock
- News Vcanbio Cell & Gene Engineering Corp., Ltd
- Tranche Update on Vcanbio Cell & Gene Engineering Corp., Ltd's Equity Buyback Plan announced on February 19, 2024.